FDA “First Generics” Policy Will Speed Some ANDA Approvals
This article was originally published in The Pink Sheet Daily
CDER Director Galson announces a revision to FDA’s generics approval process during GPhA meeting.
You may also be interested in...
Agency's ANDA review needs a top-to-bottom policy overhaul to end approval delays, Coury says.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.